5 results on '"Gelisse, R."'
Number of results to display per page
Search Results
2. Outcomes of transcatheter aortic valve replacement according to femoral or non-femoral peripheral vascular access site: A propensity-matched comparison from the French TAVI Registry
- Author
-
Beurtheret, S., primary, Karam, N., additional, Resseguier, N., additional, Com, O., additional, Gelisse, R., additional, Barra, N., additional, Tavildari, A., additional, Commeau, P., additional, Armero, S., additional, Pankert, M., additional, Siame, S., additional, Laskar, M., additional, Khanoyan, P., additional, Seitz, J., additional, Gilard, M., additional, Verhoye, J.P., additional, Eltchaninoff, H., additional, Leprince, P., additional, Le Breton, H., additional, and Houel, R., additional
- Published
- 2019
- Full Text
- View/download PDF
3. Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 Registry
- Author
-
Gilard, M., Eltchaninoff, H., Donzeau-Gouge, P., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Tchetche, D., Carrie, D., Himbert, D., Albat, B., Cribier, A., Sudre, A., Blanchard, D., Rioufol, G., Collet, F., Houel, R., Dos Santos, P., Meneveau, N., Ghostine, S., Manigold, T., Guyon, P., Grisoli, D., Le Breton, H., Delpine, S., Didier, R., Favereau, X., Souteyrand, G., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Claudel, J. -P., Bourlon, F., Bertrand, B., Laskar, M., Iung, B., Bertrand, M., Cassagne, J., Boschat, J., Lusson, J. R., Mathieu, P., Logeais, Y., Bessou, J. -P., Chevalier, B., Farge, A., Garot, P., Hovasse, T., Morice, M. C., Romano, M., Gouge, P. D., Vahdat, O., Farah, B., Dumonteil, N., Fournial, G., Marcheix, B., Nataf, P., Vahanian, A., Leclercq, F., Piot, C., Schmutz, L., Aubas, P., du Cailar, A., Dubar, A., Durrleman, N., Fargosz, F., Levy, G., Maupas, E., Rivalland, F., Robert, G., Tron, C., Juthier, F., Modine, T., Van Belle, E., Banfi, C., Sallerin, T., Bar, O., Barbey, C., Chassaing, S., Chatel, D., Le Page, O., Tauran, A., Cao, D., Dauphin, R., Durand de Gevigney, G., Finet, G., Jegaden, O., Obadia, J. -F., Beygui, F., Collet, J. -P., Pavie, A., Pecheux, Bayet, Vaillant, A., Vicat, J., Wittenberg, O., Joly, P., Rosario, R., Bergeron, P., Bille, J., Gelisse, R., Couetil, J. -P., Dubois Rande, J. -L., Hayat, D., Fougeres, E., Monin, J. -L., Mouillet, G., Arsac, F., Choukroun, E., Dijos, M., Guibaud, J. -P., Leroux, L., Elia, N., Descotes, Genon, Chocron, S., Schiele, F., Caussin, C., Azmoun, A., Nottin, R., Tirouvanziam, A., Crochet, D., Gaudin, R., Roussel, J. -C., Bonnet, N., Digne, F., Mesnidrey, P., Royer, T., Stratiev, V., Bonnet, J. -L., Cuisset, T., Abouliatim, I., Bedossa, M., Boulmier, D., Verhoye, J. P., Delepine, S., Debrux, J. -L., Furber, A., Pinaud, F., Bezon, E., Choplain, J. -N., Bical, O., Dambrin, G., Deleuze, P., Jegou, A., Lusson, J. -R., Azarnouch, K., Durel, N., Innorta, A., Lienhart, Y., Roriz, R., Staat, P., Fabiani, J. -N., Lafont, A., Zegdi, R., Heudes, D., Kindo, M., Mazzucotelli, J. -P., Zupan, M., Ivascau, C., Lognone, T., Massetti, M., Sabatier, R., Huret, B., Hochart, P., Pecheux, Bouchayer, D., Gabrielle, F., Pelissier, F., Tremeau, G., Dreyfus, G., Eker, A., Habib, Y., Hugues, N., Mialhe, C., Chavanon, O., Porcu, P., Vanzetto, G., Banfi C., Massetti M. (ORCID:0000-0002-7100-8478), Gilard, M., Eltchaninoff, H., Donzeau-Gouge, P., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Tchetche, D., Carrie, D., Himbert, D., Albat, B., Cribier, A., Sudre, A., Blanchard, D., Rioufol, G., Collet, F., Houel, R., Dos Santos, P., Meneveau, N., Ghostine, S., Manigold, T., Guyon, P., Grisoli, D., Le Breton, H., Delpine, S., Didier, R., Favereau, X., Souteyrand, G., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Claudel, J. -P., Bourlon, F., Bertrand, B., Laskar, M., Iung, B., Bertrand, M., Cassagne, J., Boschat, J., Lusson, J. R., Mathieu, P., Logeais, Y., Bessou, J. -P., Chevalier, B., Farge, A., Garot, P., Hovasse, T., Morice, M. C., Romano, M., Gouge, P. D., Vahdat, O., Farah, B., Dumonteil, N., Fournial, G., Marcheix, B., Nataf, P., Vahanian, A., Leclercq, F., Piot, C., Schmutz, L., Aubas, P., du Cailar, A., Dubar, A., Durrleman, N., Fargosz, F., Levy, G., Maupas, E., Rivalland, F., Robert, G., Tron, C., Juthier, F., Modine, T., Van Belle, E., Banfi, C., Sallerin, T., Bar, O., Barbey, C., Chassaing, S., Chatel, D., Le Page, O., Tauran, A., Cao, D., Dauphin, R., Durand de Gevigney, G., Finet, G., Jegaden, O., Obadia, J. -F., Beygui, F., Collet, J. -P., Pavie, A., Pecheux, Bayet, Vaillant, A., Vicat, J., Wittenberg, O., Joly, P., Rosario, R., Bergeron, P., Bille, J., Gelisse, R., Couetil, J. -P., Dubois Rande, J. -L., Hayat, D., Fougeres, E., Monin, J. -L., Mouillet, G., Arsac, F., Choukroun, E., Dijos, M., Guibaud, J. -P., Leroux, L., Elia, N., Descotes, Genon, Chocron, S., Schiele, F., Caussin, C., Azmoun, A., Nottin, R., Tirouvanziam, A., Crochet, D., Gaudin, R., Roussel, J. -C., Bonnet, N., Digne, F., Mesnidrey, P., Royer, T., Stratiev, V., Bonnet, J. -L., Cuisset, T., Abouliatim, I., Bedossa, M., Boulmier, D., Verhoye, J. P., Delepine, S., Debrux, J. -L., Furber, A., Pinaud, F., Bezon, E., Choplain, J. -N., Bical, O., Dambrin, G., Deleuze, P., Jegou, A., Lusson, J. -R., Azarnouch, K., Durel, N., Innorta, A., Lienhart, Y., Roriz, R., Staat, P., Fabiani, J. -N., Lafont, A., Zegdi, R., Heudes, D., Kindo, M., Mazzucotelli, J. -P., Zupan, M., Ivascau, C., Lognone, T., Massetti, M., Sabatier, R., Huret, B., Hochart, P., Pecheux, Bouchayer, D., Gabrielle, F., Pelissier, F., Tremeau, G., Dreyfus, G., Eker, A., Habib, Y., Hugues, N., Mialhe, C., Chavanon, O., Porcu, P., Vanzetto, G., Banfi C., and Massetti M. (ORCID:0000-0002-7100-8478)
- Abstract
Background Transcatheter aortic valve replacement (TAVR) has revolutionized management of high-risk patients with severe aortic stenosis. However, survival and the incidence of severe complications have been assessed in relatively small populations and/or with limited follow-up. Objectives This report details late clinical outcome and its determinants in the FRANCE-2 (FRench Aortic National CoreValve and Edwards) registry. Methods The FRANCE-2 registry prospectively included all TAVRs performed in France. Follow-up was scheduled at 30 days, at 6 months, and annually from 1 to 5 years. Standardized VARC (Valve Academic Research Consortium) outcome definitions were used. Results A total of 4,201 patients were enrolled between January 2010 and January 2012 in 34 centers. Approaches were transarterial (transfemoral 73%, transapical 18%, subclavian 6%, and transaortic or transcarotid 3%) or, in 18% of patients, transapical. Median follow-up was 3.8 years. Vital status was available for 97.2% of patients at 3 years. The 3-year all-cause mortality was 42.0% and cardiovascular mortality was 17.5%. In a multivariate model, predictors of 3-year all-cause mortality were male sex (p < 0.001), low body mass index, (p < 0.001), atrial fibrillation (p < 0.001), dialysis (p < 0.001), New York Heart Association functional class III or IV (p < 0.001), higher logistic EuroSCORE (p < 0.001), transapical or subclavian approach (p < 0.001 for both vs. transfemoral approach), need for permanent pacemaker implantation (p = 0.02), and post-implant periprosthetic aortic regurgitation grade ≥2 of 4 (p < 0.001). Severe events according to VARC criteria occurred mainly during the first month and subsequently in <2% of patients/year. Mean gradient, valve area, and residual aortic regurgitation were stable during follow-up. Conclusions The FRANCE-2 registry represents the largest database available on late results of TAVR. Late mortality is largely related to noncardiac
- Published
- 2016
4. [Does hypoalbuminemia contribute to the worsening of heart failure?]
- Author
-
Arques S, Chelaifa H, Allari JB, Gelisse R, and Roux E
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Prognosis, Pulmonary Edema complications, Frailty complications, Heart Failure etiology, Hypoalbuminemia complications, Symptom Flare Up
- Abstract
Background: Hypoalbuminemia has now emerged as a powerful prognosticator in heart failure regardless of age, clinical presentation, left ventricular ejection fraction and usual prognostic markers. Growing evidence is that this prognostic value persists after adjusting for causative factors for hypoalbuminemia such as malnutrition, inflammation and liver dysfunction., Objective: To address the prognostic relevance of hypoalbuminemia in frail elderly patients with well-characterized cardiogenic pulmonary edema at high risk for adverse outcome, beyond causative factors for low serum albumin levels. Serum albumin was measured after clinical stabilization to avoid hypervolemia., Results: In all, 67 patients with a mean age of 86 years were included. Hospital mortality was 30%. Patients who died and who survived were similar in age, ejection fraction, BNP concentration, serum creatinine, serum hemoglobin, total bilirubin and prealbumin. Patients who died had lower serum albumin levels (P<0.001), higher blood urea nitrogen (P=0.03) and higher C-reactive protein (P=0.02). In multivariate analysis, serum albumin was the sole independent predictor of hospital death (P<0.01), after adjusting for malnutrition (prealbumin P=ns), inflammation (C-reactive protein P=ns) and liver dysfunction (total bilirubin P=ns)., Conclusion: Serum albumin is a powerful prognosticator in frail elderly patients with acute cardiogenic pulmonary edema even after adjusting for main causative factors. These results suggest that hypoalbuminemia may contribute to the worsening of heart failure given the physiological properties of serum albumin that includes antioxidant activity and plasma colloid osmotic pressure action. Further studies are critically needed to address the relevance of prevention and correction of hypoalbuminemia in heart failure., (Copyright © 2020 Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
5. Femoral Versus Nonfemoral Peripheral Access for Transcatheter Aortic Valve Replacement.
- Author
-
Beurtheret S, Karam N, Resseguier N, Houel R, Modine T, Folliguet T, Chamandi C, Com O, Gelisse R, Bille J, Joly P, Barra N, Tavildari A, Commeau P, Armero S, Pankert M, Pansieri M, Siame S, Koning R, Laskar M, Le Dolley Y, Maudiere A, Villette B, Khanoyan P, Seitz J, Blanchard D, Spaulding C, Lefevre T, Van Belle E, Gilard M, Eltchaninoff H, Iung B, Verhoye JP, Abi-Akar R, Achouh P, Cuisset T, Leprince P, Marijon E, Le Breton H, and Lafont A
- Subjects
- Aged, 80 and over, Female, Femoral Artery, Follow-Up Studies, France epidemiology, Humans, Incidence, Male, Prospective Studies, Severity of Illness Index, Survival Rate trends, Time Factors, Aortic Valve surgery, Aortic Valve Stenosis surgery, Catheterization, Peripheral methods, Postoperative Complications epidemiology, Propensity Score, Registries, Transcatheter Aortic Valve Replacement methods
- Abstract
Background: Femoral access is the gold standard for transcatheter aortic valve replacement (TAVR). Guidelines recommend reconsidering surgery when this access is not feasible. However, alternative peripheral accesses exist, although they have not been accurately compared with femoral access., Objectives: This study compared nonfemoral peripheral (n-FP) TAVR with femoral TAVR., Methods: Using the data from the national prospective French registry (FRANCE TAVI [French Transcatheter Aortic Valve Implantation]), this study compared the characteristics and outcomes of TAVR procedures according to whether they were performed through a femoral or a n-FP access, using a pre-specified propensity score-based matching between groups. Subanalysis during 2 study periods (2013 to 2015 and 2016 to 2017) and among low/intermediate-low and intermediate-high/high volume centers were performed., Results: Among 21,611 patients, 19,995 (92.5%) underwent femoral TAVR and 1,616 (7.5%) underwent n-FP TAVR (transcarotid, n = 914 or trans-subclavian, n = 702). Patients in the n-FP access group had more severe disease (mean logistic EuroSCORE 19.95 vs. 16.95; p < 0.001), with a higher rate of peripheral vascular disease, known coronary artery disease, chronic pulmonary disease, and renal failure. After matching, there was no difference in the rate of post-procedural death and complications according to access site, except for a 2-fold lower rate of major vascular complications (odds ratio: 0.45; 95% confidence interval: 0.21 to 0.93; p = 0.032) and unplanned vascular repairs (odds ratio: 0.41; 95% confidence interval: 0.29 to 0.59; p < 0.001) in those who underwent n-FP access. The comparison of outcomes provided similar results during the second study period and in intermediate-high/high volume centers., Conclusions: n-FP TAVR is associated with similar outcomes compared with femoral peripheral TAVR, except for a 2-fold lower rate of major vascular complications and unplanned vascular repairs. n-FP TAVR may be favored over surgery in patients who are deemed ineligible for femoral TAVR and may be a safe alternative when femoral access risk is considered too high., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.